We have compared knockin mice with aggrecan and type II collagen resistant to aggrecanases, collagenases, or both families of enzymes, to identify the most important proteolytic driver for cartilage erosion. Specifically, the cleavage site in the aggrecan interglobular domain (IGD) of Jaffa is changed from E 373 Y 374 ALG to E 373 Y 374 NVY and the collagenase cleavage site in the a1(II) chain of Bailey is changed from PQG 775 Y 776 LAG to PPG 775 Y 776 MPG. The Jaffa mutation does not influence aggrecanase cleavage at sites in the chondroitin sulphate-rich region of aggrecan. In contrast, blocking cleavage at the primary collagenase cleavage site prevents secondary and subsequent cleavage events in Bailey type II collagen. Juniper mice are resistant to both aggrecanases and collagenases Methods: Aggrecan released into the medium from Wildtype, Bailey, Jaffa and Juniper femoral head cartilage explants (n¼ 5-6 per genotype), treated for 3 days AE IL-1, was measured by the DMMB assay. Cartilage used in the explant experiments was homozygous for all genotypes. We used the DMM surgical model of OA to compare tibial cartilage erosion in Wildtype, Bailey, Jaffa and Juniper mice at 8-weeks post-surgery. Morphological joint abnormalities in homozygous Bailey precluded their use in arthritis studies. Accordingly, the in vivo comparisons were made between heterozygous Bailey, homozygous Jaffa and Juniper mice that were heterozygous for the Bailey mutation and homozygous for the Jaffa mutation. Sagittal sections collected at 40mm intervals through the medial compartment of the knee were scored for aggrecan loss and cartilage erosion by two independent scorers blinded to the genotype. The data were analysed by the Mann-Whitney U-test Results: Aggrecan loss from explants treated with IL-1a was significantly reduced in all mutant genotypes compared with Wildtype. Juniper explants lost the least amount of aggrecan. The hierarchy of aggrecan loss was Wildtype > Jaffa > Bailey > Juniper samples. Aggrecan loss from explants treated with retinoic acid was also significantly reduced in all mutant genotypes compared with wildtype; again Juniper explants lost the least amount of aggrecan. However, with
retinoic acid treatment, the hierarchy of aggrecan loss was Wildtype > Bailey > Jaffa > Juniper samples. We measured aggrecan loss and cartilage erosion 8-weeks after DMM surgery and as predicted, found that both aggrecan loss and tibial cartilage erosion were significantly reduced in Juniper compared with Wildtype. For aggrecan loss, whereas there was no protection in Jaffa compared with Wildtype at 8 weeks, the aggrecan loss from Bailey was significantly less than for Wildtype. For cartilage erosion, both Bailey and Jaffa were protected compared with Wildtype at 8 weeks. Similarly, Juniper was better protected against cartilage erosion than either Jaffa or Bailey Conclusions: Mutations that partially block collagenolysis (heterozygous Bailey) and aggrecanolysis (homozygous Jaffa for the IGD site only) protect against cartilage erosion in experimental OA. Furthermore, protecting collagen II against collagenase attack is equal to, or better than, protecting aggrecan against IGD aggrecanase cleavage, in terms of cartilage erosion and aggrecan loss respectively (see Figure) 41 S100A8 AND S100A9 ACT AS 'PRIMERS ' Purpose: Calcium binding proteins S100A8 and S100A9 are increased in cartilage in acute and chronic inflammatory arthritis; however their role in osteoarthritis (OA) is less clear. Chondrocyte S100A8 and S100A9 mRNA are increased during the onset of surgically induced murine OA, but both are significantly downregulated as OA progresses. Interestingly, recent studies have shown that cartilage in S100A9 -/deficient mice is protected from degradation in joint instability accompanied by significant synovitis (collagenase-induced-) but not surgically-induced-OA. Whether this is due to more persistent expression of S100A8 and/or A9 or release of additional co-factors from the inflamed synovium in the collagenase model is unclear. S100A8 and S100A9, but not the heterodimer (S100A8/A9) rapidly induce MMP and ADAMTS mRNA expression in chondrocytes, but whether this leads to actual cartilage matrix breakdown has not been resolved. The aim of this study was to determine whether S100A8 or S100A9 alone or in combination with IL-1 can activate MMPs and aggrecanases with resultant chondrolysis and whether this is time-dependent. Methods: Normal ovine articular cartilage explants were cultured for 1, 2, 4, 7 or 14 days in serum-free media AE 10 -7 M human S100A8, S100A9 or S100A8/A9, with or without 10ng/ml IL-1a (n¼6/treatment). Gene expression of S100A8, S100A9, key cartilage proteins, metalloproteinases and their inhibitors was measured using qRT-PCR. Collagen and aggrecan release were measured as hydroxyproline and glycosaminoglycan respectively. Media MMP-2 and MMP-9 activity were evaluated by gelatin zymography and MMP-13 using a fluorometric assay. Results: S100A8 and S100A9 alone significantly (p<0.05) up-regulated MMP1, MMP3, S100A9, ADAMTS5 and MMP13 mRNA throughout the Ă ANCOVA results for changes in weight, BMI and cartilage volumes (mm3) and average symptoms (KOOS)
Weight, kg -9.8 -11.7 to -7.8 -12.8 -14.7 to -11.0 -8.0 -9.9 to -6. time course of the experiment (ADAMTS5 and MMP13 were not regulated at day 14), whilst the heterodimer had little effect. Interestingly, S100A9 induced greater gene expression changes than S100A8 at days 1 and 2, whilst at later time points, S100A8 induced greater changes. While there were some temporal differences, IL-1a and the S100 monomers upregulated mRNA expression of a similar spectrum of MMPs and ADAMTSs. There were also no significant differences in gene expression between IL-1a treated explants with or without addition of the S100s. Strikingly, despite the pro-catabolic gene expression changes induced by stimulation with S100A8 or S100A9, this did not translate into increased pro or active MMP-2, -9 or-13, nor did it lead to an increase in aggrecan or collagen release at any time compared with control cultures. In contrast, IL-1a stimulated increased aggrecan release and active MMP-13 in media from day 2 onwards, as well as active MMP-2 from day 4. Conclusions: Taken together this data suggests that S100A8 and S100A9 may prime the cartilage for degradation through the upregulation of pro-enzymes, however a second co-factor appears to be needed in order to activate the system and induce actual cartilage degradation. The requirement for a co-stimulatory factor(s) is reminiscent of the need for both inflammasome assembly to activate caspase-1, in concert with the effect of pro-inflammatory stimuli (TLR activation or IL-1a/TNF), in order to get secretion of active IL-1b in the innate immune response. S100A8 and S100A9 are re cognised both as ligands for TLRs; and as damage associated molecular patterns (DAMPs), many of which can activate the inflammasome/caspase1. However, expression of TLR2/4 by chondrocytes is low in normal cartilage and upregulated in OA and/or by inflammatory cytokines. We could not demonstrate synergism between IL-1a and S100s; however this may reflect an already maximal response with the dose of IL-1a used in the present study. Ongoing studies will determine if submaximal doses of IL-1a or TNFa can enhance the chondrolytic activity of S100s through upregulation of TLRs. Results: CTGF co-localised with perlecan in the PCM of human articular cartilage and was increased in OA tissue. Stimulation of cells with CTGF did not increase mRNA levels for a range of matrix proteins, nor were these affected when endogenous CTGF was knocked down by siRNA. A microarray analysis identified three strongly regulated genes: bone morphogenetic protein receptor type II (BMPR2), transmembrane prostate androgen-induced protein (TMEPAI or PMEPA1) and latent TGF-beta binding protein 2 (LTBP2). These were validated using Q-PCR and showed an early and transient response to CTGF stimulation. All three genes are known to be TGFb dependent suggesting that CTGF may be exerting its effect through TGFb-type signalling. To test this we stimulated cells with CTGF in the presence of SB431542. This abrogated the gene responses.
Conclusions:
We have identified three novel gene targets of CTGF in human articular chondrocytes and human dermal fibroblasts. The induction of these genes is dependent upon TGFb receptor signaling.
There has been much debate as to how such matricellular proteins affect cellular responses. Our data support one published theory that CTGF is able to modulate TGFb family responses (Abreu et al 2002) . The mechanism by which this occurs is being explored. Purpose: Pain and disability related to osteoarthritis (OA) may generally be considered to be chronic, but it is known that its course can be very different between patients. In this study, it is investigated whether there is a difference in development of pain and physical functioning during follow-up between two OA cohorts, Osteoarthritis Initiative (OAI) and Cohort Hip & Cohort knee study (CHECK).
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Methods: For the current study, longitudinal data of three years follow-up of the CHECK study and OA Initiative were used. The CHECK study is a Dutch prospective 10-year follow-up study, initiated by the Dutch Arthritis Association, to study progression of OA in participants with early symptomatic OA of knee or hip. Individuals were eligible if they had pain of knee or hip, were aged 45-65 years, and had not yet consulted their physician for these symptoms. In the same time in the U.S. an observational 4-year follow-up study was started to create a public archive of data, biological samples and joint images to study the natural history of, and risk factors for, the onset and progression of knee OA. In both cohorts the WOMAC was utilized to measure pain during activities (range 0-20) and physical functioning (range 0-68). For comparison with CHECK a subgroup of the incidence OAI cohort was selected which was comparable with the CHECK cohort: participants with age 45-65 years, frequent or infrequent knee symptoms and no surgery in either knee. Generalized estimating equations (GEE) were used to account for correlations within individuals and the effect modifier (OAcohort* time) was also investigated within the model. Results: For this study, the data of 688 CHECK participants with knee pain at baseline were analyzed; mean age 56 years, BMI 25 kg/m 2 and 80% female. The subgroup of OAI incidence cohort with infrequent or frequent knee pain consisted of 1417 participants, with a mean age of 56, BMI of 28 and 64% female. The CHECK cohort reported at baseline more pain and more problems in physical functioning compared to the subgroup of OAI incidence cohort (p< 0.000). A final longitudinal regression model with pain as outcome and adjusted for BMI shows that pain is 3 points lower (better health) of participants in the subgroup of OAI incidence cohort, and improves in both cohorts after 1 year of follow-up with 0.2 points, after 2 years with 0.3 points, after 3 years with 0.3 points. In a final model with function as outcome and adjusted for BMI, this outcome is 10.2 points higher (worse health) in CHECK cohort and improves in both cohorts after 1 year of follow-up with 0.6 points, after 2 years with 0.8, and after 3 years with 0.7 points. These results were not influenced by the characteristics of both cohorts (effect modifier (OAcohort* time) was not statistically significant in both outcomes).
Conclusions:
In the total group of the OAI incidence-subgroup and CHECK participants with knee pain there is a gradually improvement over 3 years time in pain and physical functioning, despite different baseline values on pain and physical functioning. In the early phase of knee OA there is overall a gradually improvement in the complaints.
